GlassScriptPhysician profile
Suthipong Soontrapa
NPI 1841511052
$8,673.09
in general payments reported to CMS, 2019-2025
41 companies · $1,876 in 2025
The $1,876 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,502 · 2020: $492 · 2021: $730 · 2022: $1,283 · 2023: $1,241 · 2024: $1,549 · 2025: $1,876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,648 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,648.04 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,034.96 | 2019-2025 | Avvigo Guidance System, Watchman Flx, Rotapro |
| Philips North America LLC | $895.82 | 2021-2024 | (9266) Elca, (Br4) Coronary Undivided |
| Abbott Laboratories | $861.56 | 2019-2025 | Diamondback Coronary, Diamondback Peripheral, Jot Dx |
| Abiomed | $838.18 | 2022-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $536.78 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $455.41 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $397.86 | 2019-2025 | Farxiga, Lokelma |
| Pfizer INC. | $397.31 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $361.33 | 2019-2025 | Lifevest |
| Amgen INC. | $333.75 | 2019-2025 | Repatha, Repatha |
| Cardiovascular Systems INC. | $292.42 | 2020-2023 | Diamondback Coronary |
| Janssen Pharmaceuticals, INC | $245.90 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.12 | 2019-2024 | Jardiance |
| Medtronic, INC. | $217.18 | 2021-2025 | Corevalve Evolut R |
| Heartflow, INC. | $210.43 | 2022-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $152.52 | 2024-2025 | Barostim Neo System |
| Bard Peripheral Vascular, INC. | $148.36 | 2019-2025 | Rotarexs 6 F X 135 Cm, Lutonix Drug Coated Balloon |
| Teleflex LLC | $144.12 | 2025 | Trapliner |
| Novo Nordisk INC | $130.56 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $75.30 | 2023-2025 | Verquvo |
| Shockwave Medical, INC | $74.33 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $70.29 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $66.81 | 2024 | |
| Sanofi-Aventis U.S. LLC | $55.80 | 2019-2024 | |
| Edwards Lifesciences Corporation | $55.42 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Genzyme Corporation | $48.57 | 2023-2024 | |
| Kestra Medical Technology Services, INC. | $48.08 | 2023 | Assure Wcd |
| Chiesi USA, INC. | $35.32 | 2021-2023 | Kengreal |
| Kiniksa Pharmaceuticals International, Plc | $34.97 | 2024 | Arcalyst |
| Corcym INC | $33.08 | 2023 | Miami Instruments |
| Daiichi Sankyo INC. | $32.07 | 2023 | Injectafer |
| W. L. Gore & Associates, INC. | $25.99 | 2023 | Gore Viabahn Endoprosthesis With Heparin |
| Terumo Medical Corporation | $17.58 | 2025 | Heartrail, Metacross Otw |
| Bridgebio Pharma, INC. | $17.50 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $17.06 | 2023 | |
| Genentech USA, INC. | $16.22 | 2022 | |
| Amarin Pharma, INC. | $13.09 | 2019 | |
| Biotronik INC. | $12.71 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $12.33 | 2019 | |
| Kls-Martin L.P. | $11.09 | 2022 | |
| Aegerion Pharmaceuticals, INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suthipong Soontrapa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.